Company Profile

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

Latest Presentation

Contact Information

Investor Relations
LHA Investor Relations
Miriam Weber Miller
T: 212-838-3777
MMiller@lhai.com

Company Contact
Cellectar Biosciences, Inc.
3301 Agriculture Drive
Madison, WI 53716
T: 608-441-8120
F: 608-441-8121
investors@cellectar.com